Arcturus Therapeutics’ (ARCT) Outperform Rating Reaffirmed at William Blair

William Blair reissued their outperform rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report released on Thursday, RTT News reports.

ARCT has been the topic of a number of other research reports. Canaccord Genuity Group lowered their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a buy rating on the stock in a report on Friday, May 10th. Citigroup boosted their target price on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a buy rating in a report on Thursday, February 8th. Finally, HC Wainwright reissued a buy rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $64.86.

Arcturus Therapeutics Trading Down 3.6 %

Arcturus Therapeutics stock opened at $31.21 on Thursday. Arcturus Therapeutics has a 12 month low of $17.52 and a 12 month high of $43.81. The business’s 50 day simple moving average is $30.19 and its 200 day simple moving average is $30.83. The company has a market cap of $840.49 million, a price-to-earnings ratio of -7.98 and a beta of 2.65.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The business had revenue of $33.99 million for the quarter, compared to analysts’ expectations of $64.14 million. As a group, equities research analysts forecast that Arcturus Therapeutics will post -4.39 earnings per share for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $35.02, for a total value of $610,573.70. Following the transaction, the chief operating officer now owns 473,448 shares of the company’s stock, valued at $16,580,148.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its stake in Arcturus Therapeutics by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock valued at $64,564,000 after acquiring an additional 146,141 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Arcturus Therapeutics by 11.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock valued at $34,336,000 after acquiring an additional 115,087 shares during the last quarter. FMR LLC boosted its position in Arcturus Therapeutics by 8.6% during the third quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock valued at $24,024,000 after buying an additional 74,081 shares during the period. Granahan Investment Management LLC boosted its position in Arcturus Therapeutics by 12.9% during the fourth quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock valued at $14,200,000 after buying an additional 51,504 shares during the period. Finally, Great Lakes Advisors LLC purchased a new stake in Arcturus Therapeutics during the fourth quarter valued at about $6,531,000. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.